Lenvima (lenvatinib)

pCPA File Number: 22016
Negotiation Status:
Concluded with an LOI
In combination with pembrolizumab, for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation
Eisai Limited
CDA-AMC Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: